SCHEMBL2956320

SCHEMBL2956320

NC(=O)c1sc2c(ccc(=O)n2-c2ccsc2)c1Nc1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 1/20 0.34
LIMK1 P53667 1/20 0.33
CXCR2 P25025 2/20 0.32
IKBKB O14920 1/20 0.32
CSF1R P07333 7/20 0.32
JAK2 O60674 2/20 0.32
JAK1 P23458 1/20 0.32
HSD11B1 P28845 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2958575 0.89 CDK4 (0.38) HPGDKDM4EALDH1A1ALOX15TSHR
SCHEMBL2958569 0.85 MAPT (0.43) HPGDKDM4EALDH1A1MAPK1HTT
SCHEMBL2952402 0.83 THRB (0.33) KDM4EALDH1A1MAPK1HTTCXCR2
SCHEMBL2952191 0.83 CSF1R (0.40) ALDH1A1CSF1RPDE4BNPC1MAPT
SCHEMBL2955899 0.82 CSF1R (0.39) HPGDALDH1A1MAPK1HTTLIMK1
SCHEMBL2960645 0.81 EGFR (0.32) HPGDKDM4EALDH1A1ALOX15TSHR
SCHEMBL2957258 0.81 CCNA2 (0.41) HPGDKDM4EALDH1A1ALOX15TSHR
SCHEMBL2955772 0.81 CYP3A4 (0.39) KDM4EALDH1A1TSHRCXCR2IKBKB
SCHEMBL2961109 0.80 LIMK2 (0.32) HPGDKDM4EALDH1A1ALOX15TSHR
SCHEMBL2958928 0.80 CXCR2 (0.38) HPGDKDM4EALDH1A1ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK HPGD 3282/4885KDM4E 2174/4885ALDH1A1 1045/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 HPGD 3563/4885KDM4E 2211/4885ALDH1A1 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.